Verrica Pharmaceuticals Inc [NASDAQ: VRCA] stock went on an upward path that rose over 30.63% on Thursday, amounting to a one-week price decrease of less than -13.69%.
Over the last 12 months, VRCA stock dropped by -61.64%. The one-year Verrica Pharmaceuticals Inc stock forecast points to a potential upside of 90.0. The average equity rating for VRCA stock is currently 1.40, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $61.87 million, with 42.41 million shares outstanding and 26.07 million shares in the current float. Compared to the average trading volume of 730.31K shares, VRCA stock reached a trading volume of 11112751 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Verrica Pharmaceuticals Inc [VRCA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VRCA shares is $14.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VRCA stock is a recommendation set at 1.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Needham have made an estimate for Verrica Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 25, 2023. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on March 22, 2023, representing the official price target for Verrica Pharmaceuticals Inc stock. Previously, the target price had yet another raise from $4 to $11, while RBC Capital Mkts kept a Outperform rating on VRCA stock. On May 25, 2022, analysts decreased their price target for VRCA shares from 16 to 4.
The Average True Range (ATR) for Verrica Pharmaceuticals Inc is set at 0.24, with the Price to Sales ratio for VRCA stock in the period of the last 12 months amounting to 4.45.
VRCA Stock Performance Analysis:
Verrica Pharmaceuticals Inc [VRCA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.69. With this latest performance, VRCA shares dropped by -36.96% in over the last four-week period, additionally sinking by -77.41% over the last 6 months – not to mention a drop of -61.64% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VRCA stock in for the last two-week period is set at 31.46, with the RSI for the last a single of trading hit 36.94, and the three-weeks RSI is set at 29.43 for Verrica Pharmaceuticals Inc [VRCA]. The present Moving Average for the last 50 days of trading for this stock 3.1998, while it was recorded at 1.4140 for the last single week of trading, and 5.8552 for the last 200 days.
Insight into Verrica Pharmaceuticals Inc Fundamentals:
Verrica Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.23 and a Current Ratio set at 2.36.
Verrica Pharmaceuticals Inc [VRCA] Institutonal Ownership Details
There are presently around $43.78%, or 66.60%% of VRCA stock, in the hands of institutional investors. The top three institutional holders of VRCA stocks are: PERCEPTIVE ADVISORS LLC with ownership of 7.1 million shares, which is approximately 15.2724%. AVORO CAPITAL ADVISORS LLC, holding 4.0 million shares of the stock with an approximate value of $$29.16 million in VRCA stocks shares; and AVORO CAPITAL ADVISORS LLC, currently with $$9.25 million in VRCA stock with ownership which is approximately 2.731%.
